respiratory
Lung cancer

Desperate cancer patients prepared to pay for immunotherapy treatment


Cancer patients desperate to buy themselves more time are spending thousands of dollars to self-fund immunotherapy treatment even though there is little evidence to show it is likely to have a major benefit. A retrospective review describing outcomes and toxicity of self-funded pembrolizumab in patients with non-melanoma solid cancers at Chris O’Brien Lifehouse has followed ...

Already a member?

Enter your email to keep reading.


OR